Hanmi Acquires Aptose Biosciences, Delisting Toronto Shares for $1.72 CAD Each
How Hanmi’s $2.41‑per‑share deal turns Aptose Biosciences into a global precision‑oncology force and what that means for investors and future growth.
3 minutes to read
APTOSE BIOSCIENCES INC
Hanmi Acquires Aptose, Delists Company After Insider Exit and Full Buyout
Whitehead Warren’s final sale ends Aptose’s TSX listing as Hanmi acquires the company, giving investors a premium exit and signaling oncology consolidation.
3 minutes to read